Black checkmark with a sparkle and a curved line underneath on a white background.
Company

VYCOR MEDICAL INC

Ticker
VYCO
Sector
Industry
Report date
November 13, 2026
Valye AI Score

63

High visibility
Recent developments
Recent developments summary

Recent news coverage does not provide direct updates on Vycor Medical's current business activities or financial performance. The latest relevant news noted a 22 percent Q2 growth reported in August 2025.

Recent developments:
  • Vycor Medical reported 22 percent growth in Q2 as of August 2025 [N1].
Overview

Vycor Medical Inc operates as a smaller reporting company with limited publicly disclosed information. The company’s financial disclosures indicate constrained liquidity and minimal profitability as of the latest quarterly filing. Vycor Medical has not reported recent revenue figures beyond 2018 in the available SEC filings. The company is subject to ordinary course litigation but has no material legal proceedings reported. Public news coverage is sparse and does not provide detailed insights into the company’s current business activities or strategic direction.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Vycor Medical Inc is a smaller reporting company with limited public disclosures. The latest SEC 10-Q filing as of September 30, 2026, shows constrained liquidity with a current ratio of 0.13 and a cash ratio of 0.04. The company reported a small net income of $738 for Q3 2026 and minimal earnings per share. The most recent revenue data dates back to mid-2018. Vycor Medical is not currently involved in material litigation. Recent news coverage does not provide substantive updates on the company’s operations or financials.

Scenarios for VYCO

Bull case model:

The company reported a modest net income in the latest quarter and had previously posted 22 percent growth in Q2 2025, indicating some operational progress. The absence of material litigation suggests manageable legal risk. These factors could support business continuity and potential operational improvements.

Bear case model:

Vycor Medical exhibits constrained liquidity with a current ratio well below 1, indicating potential short-term financial stress. The lack of recent revenue data beyond 2018 and minimal earnings per share raise concerns about sustained profitability and growth. Limited public information and news coverage reduce transparency and increase uncertainty about the company’s business prospects.

Moat:

Information on Vycor Medical's competitive advantages or market positioning is not disclosed in the available SEC filings or recent public news. The company’s smaller reporting status and limited disclosures restrict visibility into its business model and industry moat.

Risks overview
Risks summary
The primary risk for Vycor Medical is its constrained liquidity position combined with limited financial disclosure, which creates uncertainty about its ability to meet short-term obligations and sustain operations.
Risks details:

• Liquidity Risk: The company’s current ratio of 0.13 and cash ratio of 0.04 as of September 30, 2026, indicate limited short-term liquidity to cover current liabilities, posing financial risk.
• Limited Financial Disclosure: Vycor Medical’s status as a smaller reporting company results in fewer required disclosures, limiting transparency into its financial health and operations.
• Legal Risk: While no material litigation is currently reported, the company remains subject to ordinary course legal claims which could impact financials if they arise.

FINAL FORECAST FOR VYCO

Final take one line
Vycor Medical exhibits limited public disclosure and constrained liquidity, resulting in moderate visibility into its business and financial health.
Final take 12 to 24 month view

Business trends: Limited recent revenue data and modest net income reported; sparse public updates on operations.
Execution milestones: No disclosed material litigation; ongoing reporting as a smaller reporting company.
Key risks: Constrained liquidity, limited financial transparency, and potential legal claims inherent to the business.

Valye AI Visibility Research Score

High visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

63
LLM visibility overview
LLM Visibility known facts
  • Vycor Medical Inc is a smaller reporting company as defined by SEC regulations and is not required to provide extensive risk factor disclosures [S1][S2].
  • As of September 30, 2026, Vycor Medical reported cash and cash equivalents of $199,409 and current assets of $653,489, with current liabilities of $5,106,891, resulting in a current ratio of 0.13 and a cash ratio of 0.04, indicating liquidity constraints [S2].
  • The company reported net income of $738 for the quarter ending September 30, 2026, with basic and diluted earnings per share of $0 [S2].
  • Vycor Medical's most recent revenue figure available is $301,665 for the quarter ended June 30, 2018 [S2].
  • Vycor Medical is subject to litigation and claims arising in the ordinary course of business but was not involved in any material litigation as of the 2026 annual report date [S1].
  • Recent news coverage does not provide direct updates on Vycor Medical's business activities or financial performance; the latest relevant news article noted a 22 percent Q2 growth reported in August 2025 [N1].
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-31 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | INVE Tech (INVE) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/inve-tech-inve-q3-2026-earnings-call-transcript
  • N2 | 2026-11-13 | www.nasdaq.com | Flowers Foods (FLO) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/flowers-foods-flo-q3-2026-earnings-call-transcript
  • N3 | 2026-11-13 | www.nasdaq.com | Silexion Q3 Net Loss Narrows To $2.5 Mln; First Patient Dosed In SIL204 Phase 2/3 Trial | https://www.nasdaq.com/articles/silexion-q3-net-loss-narrows-25-mln-first-patient-dosed-sil204-phase-2-3-trial
  • N4 | 2026-11-13 | www.nasdaq.com | Milestone Q3 Loss Widens On CARDAMYST Launch Costs; Etripamil Phase 3 Data On Track For 2028 | https://www.nasdaq.com/articles/milestone-q3-loss-widens-cardamyst-launch-costs-etripamil-phase-3-data-track-2028
  • N5 | 2026-11-13 | www.nasdaq.com | Stocks Retreat as Chipmakers Sink and Bond Yields Rise | https://www.nasdaq.com/articles/stocks-retreat-chipmakers-sink-and-bond-yields-rise
  • N6 | 2026-11-13 | www.nasdaq.com | Stocks Pressured by Rising Bond Yields | https://www.nasdaq.com/articles/stocks-pressured-rising-bond-yields-2
  • N7 | 2026-11-13 | www.nasdaq.com | JLL: 3 Key Takeaways for Long-Term Investors | https://www.nasdaq.com/articles/jll-3-key-takeaways-long-term-investors
  • N8 | 2026-11-13 | www.nasdaq.com | Hanmi: 3 Key Takeaways for Long-Term Investors | https://www.nasdaq.com/articles/hanmi-3-key-takeaways-long-term-investors
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine